MRI Contrast Dye and Nephrogenic Systemic Fibrosis (NSF) Nephrogenic Fibrosing Dermotherapy (NFD)

MRI stands for Magnetic Resonance Imaging, and is a medical imaging device used to view any internal part of the body. Used for brain scanning, cardiovascular, skeletal and cancer imaging.

Nephrogenic systemic fibrosis associated with gadolinium exposure during MRI

NSF is a rare multisystemic fibrosing disorder that primarily affects the skin but may affect other organs of patients with renal (kidney) problems.

Studies provided by the American Roentgen Ray Society illustrate a risk factor associated with gadolinium based contrast dyes that are commonly used during an MRI scan. The study shows that the development of NFS takes place in patients within 2-11 weeks after gadodiamide administration. It should be noted that this condition mainly appears in people with end-stage renal (kidney) disease.

Symptoms and Diagnosis of Nephrogenic systemic fibrosis (NSF)

Swelling of the skin
Skin tightening
Muscle weakness
Skin discoloration
Hardened patches of skin
Reddened or darkened patches of skin
Skin may look and feel similar to an orange peel
Burning, itching or severe pain

MRI Contrast Dye

Contrast dye is a liquid solution that is injected into a person undergoing either an MRI or MRA scan. This dye can be injected into the blood veins, taken orally, or inserted into the rectum. The primary purpose of contract dye is to highlight and allow for better details of the MRI image. Contrast dye works by altering the magnetic properties of the tissue.

The most commonly used brands of MRI contrast dyes that contain gadolinium are ProHance, MultiHance, Omniscan, OptiMARK, and Magnevist brand.

FDA issues Black Box Warning on Gadolinium based contract dyes.

FDA notified healthcare professionals of the Agency's request for the addition of a boxed warning and new warnings about the risk of nephrogenic systemic fibrosis (NSF) to the full prescribing information for all gadolinium-based contrast agents (GBCAs). The new prescribing information FDA is requesting highlights and describes the risk for NSF following exposure to a GBCA in patients with acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2) and patients with acute renal insufficiency of any severity due to the hepato-renal syndrome or in the peri-operative liver transplantation period. Healthcare professionals should avoid the use of a GBCA in these patients unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging.

First Name
Last Name
Phone - -
Email
Address
Zip
Comments
By clicking the "Submit" button below, you agree that law firms you are matched with may contact you by telephone even if you are on a federal or state Do Not Call registry. Up to 10 law firms may respond to your request within approximately 2 weeks. In some cases 3 or more firms may respond to your request after 30 days. Use of this site is subject to our Terms of Use.

By leaving this box checked, I agree to receive future advertisements and announcements from our firm, its affiliates and partners.
I agree that submitting this form and the information contained within does not establish an attorney client relationship.
I agree that my information will be reviewed by more than one attorney and/or law firm.
I agree that the information that I will receive in response to the above question is general information and I will not be charged for the response to this e-mail question and I further understand that the law for each state may vary, and therefore, I will not rely upon this information as legal advice. Since this matter may require advice regarding my home state, I agree that local counsel may be contacted for referral of this matter.
By clicking the Submit button, I agree to wiselawgroup’s Privacy Policy and Terms and Conditions and I am also providing my express consent to receive pre-recorded marketing messages from wiselawgroup, it’s affiliates and partners as set forth here.